Current status of antihistamines repurposing for infectious diseases

TL;DR

This review assesses the potential of antihistamines as anti-infective agents, highlighting promising in vitro results and the need for systematic preclinical trials to advance repurposing efforts for infectious diseases.

Contribution

It compiles existing data on antihistamines' activity against pathogens and emphasizes research gaps hindering clinical application.

Findings

12 antihistamines show activity against various pathogens

In vitro activity of antihistamines is generally in low to sub-microM range

Limited in vivo and preclinical trials hinder clinical translation

Abstract

Objectives. This review gathers information on the potential role of antihistamines as anti-infective agents and identifies gaps in research that have impaired its applicability in human health. Methods. The literature search encompassed MEDLINE, PubMed and Google Scholar from 1990 to 2022. Results. The literature search identified 12 antihistamines with activity against different pathogens. Eight molecules were second-generation antihistamines with intrinsically lower tendency to cross the blood brain barrier thereby with reduced side effects. Only five antihistamines had in vivo evaluations in rodents while one study utilized a wax moth model to determine astemizole anti-Cryptococcus sp. activity combined with fluconazole. In vitro studies showed that clemastine was active against Plasmodium, Leishmania, and Trypanosoma, while terfenadine suppressed Candida spp. and Staphylococcus aureus growth. In vitro assays found that SARS-coV-2 was inhibited by doxepin, azelastine, desloratadine, and clemastine. Different antihistamines inhibited Ebola virus (diphenhydramine, chlorcyclizine), Hepatitis C virus (chlorcyclizine), and Influenza virus (carbinoxamine, chlorpheniramine). Generally, in vitro activity (IC50) of antihistamines was in the low to sub-microM range, except for Staphylococcus epidermidis (loratadine MIC=50 microM) and SARS-coV-2 (desloratadine 70% inhibition at 20 microM). Conclusion. Many antihistamine drugs showed potential to progress to clinical trials based on in vitro data and availability of toxicological and pharmacological data. However, the overall lack of systematic preclinical trials has hampered the advance of repurposed antihistamines for off label evaluation. The low interest of pharmaceutical companies has to be counterbalanced through collaborations between research groups, granting agencies and government to support the needed clinical trials.